DHA Laboratory: Training and Research

What this domain tests

This domain covers the governance of research and clinical training alongside care delivery: ethical review, informed consent, research integrity, data protection, and the supervision of trainees involved in studies.

Concepts to master

• Research ethics review: studies involving human participants require approval from an ethics committee before commencement; amendments also require approval.
• Informed consent: voluntary, informed, and documented. Vulnerable groups need additional safeguards, and consent can be withdrawn.
• Research integrity: honest reporting, avoiding fabrication, falsification, and plagiarism, declaring conflicts of interest, and managing data securely.
• Confidentiality and data protection: anonymisation reduces risk; identifiable data require a lawful basis and safeguards.
• Training within research: trainees must be supervised and must not perform research procedures beyond their competence.

Traps

1. Assuming ethics approval is a one-off; protocol changes need re-approval.
2. Treating consent as a signature rather than an ongoing process.
3. Believing anonymised data are always risk-free; re-identification is possible with small datasets.
4. Overlooking that a conflict-of-interest declaration is required even when the conflict seems minor.

Rule of thumb

Before any participant contact, confirm three things: ethics approval, valid consent, and a lawful data-handling plan. If any is missing, the study cannot proceed.

Worked example: A researcher wants to add a blood test to an approved study. Because this changes the protocol and participant burden, the correct step is to seek an ethics amendment and updated consent, not to proceed under the original approval.

Public Health

What this domain tests

Public health questions focus on population-level health: measuring disease burden, identifying risk factors, planning interventions, and understanding the health system's preventive role.

Concepts to master

• Levels of prevention: primary (prevent onset), secondary (early detection), tertiary (limit disability). Know which intervention belongs to which level.
• Core functions: assessment (surveillance and monitoring), policy development, and assurance (ensuring services are delivered).
• Epidemiological measures: incidence (new cases over time) versus prevalence (all existing cases at a point).
• Determinants of health: biological, behavioural, social, environmental, and economic factors.
• Screening principles: a good screening test targets a significant condition, has acceptable sensitivity and specificity, and is followed by confirmatory testing.

Traps

1. Mixing incidence and prevalence; a longer survival time raises prevalence without changing incidence.
2. Calling a screening test diagnostic; screening identifies suspects and needs confirmation.
3. Mislabeling vaccination as secondary prevention; it is usually primary.
4. Assuming a sensitive test is also specific; trade-offs are common.

Rule of thumb

Classify by timing relative to disease: before onset → primary; early, asymptomatic phase → secondary; after disease is established → tertiary.

Worked example: A programme offers mammography to asymptomatic women to detect early breast cancer. This is secondary prevention, because the aim is early detection rather than prevention of onset.

Prevention and Immunisation

What this domain tests

Immunisation questions test vaccine science, schedules, safety, and cold-chain practice, plus the population strategy behind them.

Concepts to master

• Immunity types: active (vaccine or infection induces a response) versus passive (antibodies given, short-lived).
• Herd immunity: high coverage protects those who cannot be vaccinated; the threshold rises with transmissibility.
• Vaccine types: live attenuated, inactivated, toxoid, subunit, and mRNA. Live vaccines generally require caution in immunocompromised people and have specific spacing rules.
• Cold chain: vaccines must be stored within the recommended temperature range; breaches require assessment before use.
• Adverse events: distinguish common expected reactions from serious events; reporting systems exist for the latter.

Traps

1. Confusing active with passive immunity; immunoglobulin provides immediate but temporary protection.
2. Assuming a missed dose requires restarting a schedule; most schedules resume rather than restart.
3. Believing a cold-chain breach always means discarding; the correct step is assessment against the protocol.
4. Forgetting that contraindications differ between live and inactivated vaccines.

Rule of thumb

For any immunisation scenario, check four items: is the vaccine appropriate for this person, is the schedule correct, has storage been maintained, and is there a contraindication?

Worked example: A child misses a scheduled dose by several weeks. The correct action is to give the missed dose as soon as possible and continue the schedule from that point, not to restart the series.